1. Akinyemiju T. et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level//JAMA Oncol. 2017. Vol. 3, N 12. P. 1683.

2. Estes C. et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease//Hepatology. 2018. Vol. 67, N 1. P. 123 - 133.

3. Fattovich G. et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors//Gastroenterology. W.B. Saunders, 2004. Vol. 127, N 5 SUPPL.

4. Карпин А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2020. 252 p.

5. AJCC Cancer Staging Manual. 8th ed.//ed. Amin M.B. et al. Springer, 2017.

6. Galle P.R. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma//J. Hepatol. Elsevier B.V., 2018. Vol. 69, N 1. P. 182 - 236.

7. Forner A., Reig M., Bruix J. Hepatocellular carcinoma//The Lancet. Lancet Publishing Group, 2018. Vol. 391, N 10127. P. 1301 - 1314.

8. Vogel A. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. Oxford University Press, 2018. Vol. 29. P. iv238 - iv255.

9. Marrero J.A. et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases//Hepatology. John Wiley and Sons Inc., 2018. Vol. 68, N 2. P. 723 - 750.

10. Terrault N.A. et al. AASLD guidelines for treatment of chronic hepatitis B//Hepatology. John Wiley and Sons Inc., 2016. Vol. 63, N 1. P. 261 - 283.

11. Chung R.T. et al. Hepatitis C guidance 2018 update: Aasld-idsa recommendations for testing, managing, and treating Hepatitis C Virus infection//Clin. Infect. Dis. Oxford University Press, 2018. Vol. 67, N 10. P. 1477 - 1492.

12. Waidely E. et al. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection//Analyst. Royal Society of Chemistry, 2016. Vol. 141, N 1. P. 36 - 44.

13. Arrieta O. et al. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis//BMC Cancer. 2007. Vol. 7.

14. NCCN. Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers, version 4.2021. 2021.

15. Peng Y., Qi X., Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis//Medicine (Baltimore). 2016. Vol. 95, N 8. P. e2877.

16. Forner A. et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma//Hepatology. 2008. Vol. 47, N 1. P. 97 - 104.

17. Chou R. et al. Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma//Ann. Intern. Med. 2015. Vol. 162, N 10.

18. Lee Y.J. et al. Hepatocellular carcinoma: Diagnostic performance of multidetector CT and MR imaging - a systematic review and meta-analysis//Radiology. Radiological Society of North America Inc., 2015. Vol. 275, N 1. P. 97 - 109.

19. Liu X. et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis//Liver Transplant. 2017. Vol. 23, N 12. P. 1505 - 1518.

20. Li J. et al. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies//European Radiology. 2019. Vol. 29, N 12. P. 6519 - 6528.

21. Guo J. et al. Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis//Abdom. Radiol. Springer New York LLC, 2016. Vol. 41, N 10. P. 1960 - 1972.

22. Kang T.W. et al. Use of gadoxetic acid-enhanced liver MRI and mortality in more than 30000 patients with hepatocellular Carcinoma: A nationwide analysis//Radiology. 2020. Vol. 295, N 1. P. 114 - 124.

23. Wang J.H. et al. Clinical Impact of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study//Dig. Dis. Sci. 2016. Vol. 61, N 4. P. 1197 - 1205.

24. Cerny M. et al. LI-RADS version 2018 ancillary features at MRI//Radiographics. Radiological Society of North America Inc., 2018. Vol. 38, N 7. P. 1973 - 2001.

25. Chernyak V. et al. LI-RADS (R) algorithm: CT and MRI//Abdominal Radiology. Springer New York LLC, 2018. Vol. 43, N 1. P. 111 - 126.

26. Ludwig D.R. et al. Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict L//HPB. Elsevier B.V., 2019. Vol. 21, N 12. P. 1697 - 1706.

27. Choi J.Y., Lee J.M., Sirlin C.B. CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features//Radiology. 2014. Vol. 273, N 1. P. 30 - 50.

28. Katyal S. et al. Extrahepatic Metastases of Hepatocellular Carcinoma//Radiology. 2000. Vol. 216, N 3. P. 698 - 703.

29. Natsuizaka M. et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases//J. Gastroenterol. Hepatol. Blackwell Publishing, 2005. Vol. 20, N 11. P. 1781 - 1787.

30. Stewart C.J.R., Coldewey J., Stewart I.S. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions//J. Clin. Pathol. 2002. Vol. 55, N 2. P. 93 - 97.

31. Sangiovanni A. et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis//Gut. 2010. Vol. 59, N 5. P. 638 - 644.

32. Intenzo C., Kim S., Lakhani P. Utility of FDG-PET/CT in Detecting Metastases from Hepatocellular Carcinoma//J. Nucl. Med. 2017. Vol. 58, Issue. P. 427.

33. Marrero J.A. et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort//Hepatology. 2005. Vol. 41, N 4. P. 707 - 715.

34. Cillo U. et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system//J. Hepatol. 2006. Vol. 44, N 4. P. 723 - 731.

35. Chen C.-H. et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - Analysis of 2010 Taiwanese patients//Eur. J. Cancer. 2009. Vol. 45, N 9. P. 1630 - 1639.

36. Kumar A. et al. Hepatic arteriovenous fistulae: Role of interventional radiology//Dig. Dis. Sci. 2012. Vol. 57, N 10. P. 2703 - 2712.

37. Wu H. et al. Clinical characteristics of hepatic Arterioportal shunts associated with hepatocellular carcinoma//BMC Gastroenterol. 2018. Vol. 18, N 1.

38. Truty M.J., Vauthey J.-N. Surgical Resection of High-Risk Hepatocellular Carcinoma: Patient Selection, Preoperative Considerations, and Operative Technique//Ann. Surg. Oncol. 2010. Vol. 17, N 5. P. 1219 - 1225.

39. Pawlik T.M. Critical Appraisal of the Clinical and Pathologic Predictors of Survival After Resection of Large Hepatocellular Carcinoma//Arch. Surg. 2005. Vol. 140, N 5. P. 450.

40. Chok K.S. et al. Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma//Br. J. Surg. 2009. Vol. 96, N 1. P. 81 - 87.

41. Ribero D. et al. Selection for resection of hepatocellular carcinoma and surgical strategy: Indications for resection, evaluation of liver function, portal vein embolization, and resection//Annals of Surgical Oncology. 2008. Vol. 15, N 4. P. 986 - 992.

42. Berzigotti A. et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis//Hepatology. John Wiley and Sons Inc., 2015. Vol. 61, N 2. P. 526 - 536.

43. Mazzaferro V. et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors//Am. J. Transplant. 2016. Vol. 16, N 10. P. 2892 - 2902.

44. Mazzaferro V., Battiston C., Sposito C. Pro (With Caution): Extended oncologic indications in liver transplantation//Liver Transplant. 2018. Vol. 24, N 1. P. 98 - 103.

45. Mazzaferro V. et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial//Lancet Oncol. 2020. Vol. 21, N 7. P. 947 - 956.

46. Clavien P.A. et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report//The Lancet Oncology. 2012. Vol. 13, N 1.

47. Олисов О.Д. et al. Трансплантация печени в лечении нерезектабельной гепатоцеллюлярной карциномы в отсутствие цирроза печени.//Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018. Vol. 28, N 4. P. 76 - 83.

48. Новзурбеков М.С. et al. Трансплантация и аутотрансплантация как радикальный метод лечения нерезектабельных опухолевых и паразитарных заболеваний печени//Анналы хирургической гепатологии. 2020. Vol. 25, N 4. P. 49 - 59.

49. Decaens T., Laurent A., Luciani A. Liver transplantation for hepatocellular carcinoma in non-cirrhotic livers regardless of the number and size of tumours?//Journal of Hepatology. 2012. Vol. 57, N 2. P. 235 - 236.

50. Fujiki M., Aucejo F., Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Necessity or option?//Liver International. 2011. Vol. 31, N 8. P. 1081 - 1089.

51. Majno P., Giostra E., Mentha G. Management of hepatocellular carcinoma on the waitng list before liver transplantation: Time for controlled trials?//Liver Transplant. 2007. Vol. 13, N 11 SUPPL. 2.

52. Yin J. et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study//J. Clin. Oncol. 2013. Vol. 31, N 29. P. 3647 - 3655.

53. Huang G. et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma//Ann. Surg. Lippincott Williams and Wilkins, 2015. Vol. 261, N 1. P. 56 - 66.

54. Dang H. et al. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West//Hepatology. John Wiley and Sons Inc., 2020. Vol. 71, N 6. P. 1910 - 1922.

55. Cabibbo G. et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients//J. Hepatol. 2019. Vol. 71, N 2. P. 265 - 273.

56. Lin W.C. et al. Impact of direct-acting antiviral therapy for hepatitis C - related hepatocellular carcinoma//PLoS One. 2020. Vol. 15, N 5.

57. Tiong L., Maddern G.J. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma//Br. J. Surg. 2011. Vol. 98, N 9. P. 1210 - 1224.

58. Germani G. et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis//J. Hepatol. 2010. Vol. 52, N 3. P. 380 - 388.

59. Zhu Z.X. et al. Radiofrequency ablation with or without ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis.//Minerva Med. 2016. Vol. 107, N 6. P. 381 - 391.

60. Wang W., Shi J., Xie W.-F. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis//Liver Int. 2010. Vol. 30, N 5. P. 741 - 749.

61. Ni J. et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis//J. Cancer Res. Clin. Oncol. 2013. Vol. 139, N 4. P. 653 - 659.

62. Tian G. et al. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis//BMJ Open. 2018. Vol. 8, N 10. P. e021269.

63. Erridge S. et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma//British Journal of Surgery. John Wiley and Sons Ltd, 2017. Vol. 104, N 11. P. 1433 - 1442.

64. Lencioni R.A. et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection//Radiology. 2003. Vol. 228, N 1. P. 235 - 240.

65. Lin S.M. et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less//Gut. 2005. Vol. 54, N 8. P. 1151 - 1156.

66. Cho Y.K. et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies//Hepatology. 2009. Vol. 49, N 2. P. 453 - 459.

67. Luo W. et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis//World J. Surg. Oncol. 2017. Vol. 15, N 1. P. 126.

68. Crocetti L. et al. CIRSE Standards of Practice on Thermal Ablation of Liver Tumours//Cardiovasc. Intervent. Radiol. Springer, 2020. Vol. 43, N 7. P. 951 - 962.

69. Gupta P. et al. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis//Eur. Radiol. Springer Science and Business Media Deutschland GmbH, 2021. Vol. 31, N 7. P. 5400 - 5408.

70. Weis S. et al. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma//Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2015. Vol. 2017, N 6.

71. Robbins J.R. et al. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival//Cancer Med. 2019. Vol. 8, N 3. P. 928 - 938.

72. Zhang H. et al. Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis//Futur. Oncol. Future Medicine Ltd, 2021.

73. Bruix J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial//Lancet Oncol. 2015. Vol. 16, N 13. P. 1344 - 1354.

74. Rand T. et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate//Cardiovasc. Intervent. Radiol. 2005. Vol. 28, N 3. P. 313 - 318.

75. Bonomo G. et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: First clinical experience and one-year follow-up//Cardiovasc. Intervent. Radiol. 2010. Vol. 33, N 3. P. 552 - 559.

76. Llovet J.M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial//Lancet. 2002. Vol. 359, N 9319. P. 1734 - 1739.

77. Affonso B.B. et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging//World J. Gastroenterol. Baishideng Publishing Group Co, 2019. Vol. 25, N 37. P. 5687 - 5701.

78. Lo C.M. et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma//Hepatology. 2002. Vol. 35, N 5. P. 1164 - 1171.

79. C. et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials//Radiology. 2002. Vol. 224, N 1. P. 47 - 54.

80. Raoul J.L. et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization//Cancer Treatment Reviews. 2011. Vol. 37, N 3. P. 212 - 220.

81. Forner A. et al. Treatment of intermediate-stage hepatocellular carcinoma//Nature Reviews Clinical Oncology. Nature Publishing Group, 2014. Vol. 11, N 9. P. 525 - 535.

82. de Baere T. et al. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion//Cardiovasc. Intervent. Radiol. 2016. Vol. 39, N 3. P. 334 - 343.

83. Silva J.P. et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis//HPB. 2017. Vol. 19, N 8. P. 659 - 666.

84. Lencioni R., Llovet J.M. Modified recist (mRECIST) assessment for hepatocellular carcinoma//Seminars in Liver Disease. 2010. Vol. 30, N 1. P. 52 - 60.

85. Cerrito L. et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers//World Journal of Gastroenterology. 2019. Vol. 25, N 31. P. 4360 - 4382.

86. Chino F. et al. The role of external beam radiotherapy in the treatment of hepatocellular cancer//Cancer. 2018. Vol. 124, N 17. P. 3476 - 3489.

87. Llovet J.M. et al. Sorafenib in Advanced Hepatocellular Carcinoma//N. Engl. J. Med. 2008. Vol. 359, N 4. P. 378 - 390.

88. Cheng A.L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial//Lancet Oncol. 2009. Vol. 10, N 1. P. 25 - 34.

89. Bruix J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial//J. Hepatol. 2012. Vol. 57, N 4. P. 821 - 829.

90. Kudo M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial//Lancet. 2018. Vol. 391, N 10126. P. 1163 - 1173.

91. Bruix J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial//Lancet. Lancet Publishing Group, 2017. Vol. 389, N 10064. P. 56 - 66.

92. Abou-Alfa G.K. et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma//N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2018. Vol. 379, N 1. P. 54 - 63.

93. Finn R.S. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma//N. Engl. J. Med. 2020. Vol. 382, N 20. P. 1894 - 1905.

94. El-Khoueiry A.B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial//Lancet. 2017. Vol. 389, N 10088. P. 2492 - 2502.

95. Zhu A.X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial//Lancet Oncol. 2019. Vol. 20, N 2. P. 282 - 296.

96. Finn R.S. et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).//J. Clin. Oncol. 2019. Vol. 37, N 15_suppl. P. 4004 - 4004.

97. Yau T. et al. Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial//JAMA Oncology. 2020. Vol. 6, N 11.

98. Qin S. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia//J. Clin. Oncol. 2013. Vol. 31, N 28. P. 3501 - 3508.

99. Zaanan A. et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study//J. Hepatol. 2013. Vol. 58, N 1. P. 81 - 88.

100. Chakrabarti S. et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.//J. Clin. Oncol. 2019. Vol. 37, N 4_suppl. P. 393 - 393.

101. Tovoli F. et al. Radiologic criteria of response to systemic treatments for hepatocellular carcinoma//Hepatic Oncol. Future Medicine Ltd, 2017. Vol. 4, N 4. P. 129 - 137.

102. Angeli P. et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis//J. Hepatol. Elsevier B.V., 2018. Vol. 69, N 2. P. 406 - 460.

103. Kim J.H. et al. Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma//Dig. Dis. Sci. 2016. Vol. 61, N 11. P. 3354 - 3362.

104. Gentilini P. et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial//J. Hepatol. 1999. Vol. 30, N 4. P. 639 - 645.

105. Bernardi M. et al. Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials//Hepatology. 2012. Vol. 55, N 4. P. 1172 - 1181.

106. Luther A. et al. The Impact of Total Body Prehabilitation on Post-Operative Outcomes After Major Abdominal Surgery: A Systematic Review//World Journal of Surgery. 2018. Vol. 42, N 9. P. 2781 - 2791.

107. Arends J. et al. ESPEN guidelines on nutrition in cancer patients//Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, N 1. P. 11 - 48.

108. Possa S.S. et al. Implementation of a guideline for physical therapy in the postoperative period of upper abdominal surgery reduces the incidence of atelectasis and length of hospital stay//Rev. Port. Pneumol. 2014. Vol. 20, N 2. P. 69 - 77.

109. Lewis L.K., Williams M.T., Olds T.S. The active cycle of breathing technique: A systematic review and meta-analysis//Respiratory Medicine. 2012. Vol. 106, N 2. P. 155 - 172.

110. Cho I. et al. Feasibility and effects of a postoperative recovery exercise program developed specifically for gastric cancer patients (PREP-GC) undergoing minimally invasive gastrectomy//J. Gastric Cancer. 2018. Vol. 18, N 2. P. 118 - 133.

111. Hunter E.G., Baltisberger J. Functional outcomes by age for inpatient cancer rehabilitation: A retrospective chart review//Journal of Applied Gerontology. 2013. Vol. 32, N 4. P. 443 - 456.

112. Грушина Т.И. Реабилитация в онкологии: физиотерапия. ГЭОТАР-Мед. Москва, 2006. 240 p.

113. Ajani J.A. et al. Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology//JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press, 2016. Vol. 14, N 10. P. 1286 - 1312.

114. Bland K.A. et al. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research//Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd, 2019. Vol. 136. P. 79 - 85.

115. Streckmann F. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review//Sports medicine (Auckland, N.Z.). 2014. Vol. 44, N 9. P. 1289 - 1304.

116. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy//J. Thorac. Dis. 2018. Vol. 10, N S35. P. S4391 - S4399.

117. Lee J.M. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy.//J. Clin. Oncol. 2012. Vol. 30, N 15_suppl. P. 9019 - 9019.

118. Rick O. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase - III study//Bioelectromagnetics. 2017. Vol. 38, N 2. P. 85 - 94.

119. Finkelmeier F., Waidmann O., Trojan J. Nivolumab for the treatment of hepatocellular carcinoma//Expert Rev. Anticancer Ther. 2018. Vol. 18, N 12. P. 1169 - 1175.

120. Zhao X. et al. Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types//Clinical Trials. American Association for Cancer Research, 2017. P. CT101 - CT101.

121. Chia W.K. et al. Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma//Annals Academy of Medicine Singapore. - 2008. - Т. 37. - N. 7. - С. 554

122. Fallon M., Giusti R., Aielli F., et al. Management of Cancer Pain in Adult Patients//ESMO Clinical Practice Guidelines Ann Oncol (2018) 29 (Suppl 4): iv166 - iv191.

123. Efthimiou O, Nikolakopoulou A, Salanti G. Network Meta-Analysis of Evidence Comparing Analgesics for Cancer Pain Management Initiation & Maintenance and for Breakthrough Cancer Pain. World Health Organization Guideline. https://www.who.int/ncds/management/palliative-care/Cancer-pain-guidelines-Annex-7.pdf.

124. Lin Liu 1, Ying-Hui Zheng, Li Han, Shu-Kui Qin. Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies//Medicine (Baltimore) 2016 Oct; 95(40): e4993. doi: 10.1097/MD.0000000000004993.

125. Choi J.O. et al. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection//Hepatology, Vol. 73, No. 2, 2021, 661 - 673

126. Singal A. et al. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma//Gastroenterology 2019; 157: 1253 - 1263

127. Zhou C, Peng Y, Zhou K, et al. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2019 Feb; 8(1): 19 - 28.

128. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022 Apr; 76(4): 959 - 974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30